Literature DB >> 17981332

Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues.

Corbett J A Reinbold1, Subramaniam Malarkannan.   

Abstract

Immune specificity of a T cell is determined by the TCR contact residues exposed on the antigenic peptide/MHC complex. Naturally processed, biallelic epitopes from H7 minor histocompatibility (mH) antigen vary in position 7 (p7) from aspartic acid (D) to a glutamic acid (E), which differ by an additional methylene (-CH(2)) in the side chain. Here, we show that this variation generates a strong anti-H7a or anti-H7b cytotoxic T cell responses. Further, the H7 allelic peptides use p6 asparagine as their central anchor residue and amino acid variations in either the canonical p5 or the predicted p6 anchor positions in the antigenic epitope were detrimental for TCR recognition. In addition, introduction of any other amino acids, except asparagine, in the polymorphic p7 significantly abolished the ability of anti-H7b TCR recognition. This demonstrates that only an asparagine with an amine group as a side chain instead of a charged oxygen radical could effectively stimulate the anti-H7b specific T cells. Our findings provide evidence that mH antigen-specific TCRs are highly stringent in recognizing their cognate epitopes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981332      PMCID: PMC3835348          DOI: 10.1016/j.molimm.2007.09.017

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  29 in total

1.  Generation of antigen-specific, lacZ-inducible T-cell hybrids.

Authors:  S Malarkannan; L M Mendoza; N Shastri
Journal:  Methods Mol Biol       Date:  2001

2.  How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination.

Authors:  David A Ostrov; Matthew M Roden; Wuxian Shi; Edith Palmieri; Gregory J Christianson; Lisa Mendoza; Gilbert Villaflor; Darcie Tilley; Nilabh Shastri; Howard Grey; Steven C Almo; Derry Roopenian; Stanley G Nathenson
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein.

Authors:  Eric Spierings; Anthony G Brickner; Jennifer A Caldwell; Suzanne Zegveld; Nia Tatsis; Els Blokland; Jos Pool; Richard A Pierce; Sahana Mollah; Jeffrey Shabanowitz; Laurence C Eisenlohr; Peter van Veelen; Ferry Ossendorp; Donald F Hunt; Els Goulmy; Victor H Engelhard
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

Review 4.  Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire.

Authors:  Victor H Engelhard; Anthony G Brickner; Angela L Zarling
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

5.  Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.

Authors:  P Fontaine; G Roy-Proulx; L Knafo; C Baron; D C Roy; C Perreault
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

6.  The model B6(dom1) minor histocompatibility antigen is encoded by a mouse homolog of the yeast STT3 gene.

Authors:  Kevin McBride; Chantal Baron; Serge Picard; Stéphanie Martin; Daniel Boismenu; Alex Bell; John Bergeron; Claude Perreault
Journal:  Immunogenetics       Date:  2002-10-02       Impact factor: 2.846

7.  Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide.

Authors:  Eun Young Choi; Gregory J Christianson; Yoshitaka Yoshimura; Thomas J Sproule; Nadja Jung; Sebastian Joyce; Derry C Roopenian
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

Review 8.  T-cell therapy of leukemia.

Authors:  Stanley R Riddell; Makoto Murata; Sophia Bryant; Edis H Warren
Journal:  Cancer Control       Date:  2002 Mar-Apr       Impact factor: 3.302

Review 9.  Towards patient-specific tumor antigen selection for vaccination.

Authors:  Hans-Georg Rammensee; Toni Weinschenk; Cécile Gouttefangeas; Stefan Stevanović
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

10.  Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.

Authors:  Tuna Mutis; Els Blokland; Michel Kester; Ellen Schrama; Els Goulmy
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

View more
  2 in total

1.  Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.

Authors:  Julie S Nielsen; Andrew R Chang; Darin A Wick; Colin G Sedgwick; Zusheng Zong; Andrew J Mungall; Spencer D Martin; Natalie N Kinloch; Susann Ott-Langer; Zabrina L Brumme; Steven P Treon; Joseph M Connors; Randy D Gascoyne; John R Webb; Brian R Berry; Ryan D Morin; Nicol Macpherson; Brad H Nelson
Journal:  Oncoimmunology       Date:  2017-04-28       Impact factor: 8.110

Review 2.  H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.

Authors:  Eun Young Choi; Kyungho Choi; Giri Nam; Woojin Kim; Minho Chung
Journal:  Front Immunol       Date:  2020-06-10       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.